Rhinomed (ASX:RNO) is pleased to advise investors that it has entered into a new distribution agreement with, and received an initial order for
stock from a new retailer. The retailer is one of America's largest pharmacy retailers.
Rhinomed (ASX:RNO) a leader in nasal respiratory technology, today announced a pivotal year of growth and milestone achievement. The company can report record recognised revenues for FY18 Q4 of $874k - a 71% increase over FY18 Q3 and totalling $2.13m for the full FY18, up 24% on FY17.Read More
RNO is pleased to advise investors that it has signed a non-binding term sheet with Columbia Care LLC to license RNO's nasal platform for the delivery of medical cannabis and cannabinoid compounds, analogues and derivatives.Read More